

**PRESS RELEASE****Novartis Hellas: Presentation of the Corporate Responsibility Report  
2016-2017**

Company's contribution to the Greek society and economy is valued at 35% of its turnover.

**Athens, July 17th 2018** – Its consistent orientation towards the principles of sustainable development and its focus on patients and the Greek society in general demonstrate the data and measurements presented by Novartis Hellas in the context of the Corporate Responsibility Report 2016-2017, developed by EY.

Focused on its mission to discover new ways to improve people's quality of life and extend life expectancy, Novartis Hellas has incorporated the principles of Corporate Responsibility into its mode of operation with concrete measurable initiatives focusing on two main pillars of action: expanding access to healthcare and responsible business.

An important element is that in the period 2016-2017, Novartis Hellas returned to Greek society and economy 35% of its turnover. In particular, the company has made total investments of more than € 290 million through fiscal contributions, payroll, research and development, donations, sponsorships, social programs, clawback and rebates.

Company's investment in conducting over 100 clinical studies with 5,500 patients exceeded EUR 7,6 million by promoting scientific innovation and supporting jobs. The company also cooperated with Greek pharmaceutical companies to promote pharmaceutical products through an investment of € 36.5 million, while continuing to strengthen the Greek supply chain by keeping the percentage of indirect purchases from domestic suppliers at 95.7% contributing further to boosting entrepreneurship and employment.

Subscribing each person's right to health, the company has implemented 3 prevention programs by providing 20,000 free diagnostic tests in 17 areas across the country, 5 awareness campaigns for major diseases in collaboration with science and patient associations, and 18 patient support programs for major oncological, neurological and rheumatic diseases. Novartis Hellas also stood by 34 patient associations, donated drugs and supported research projects of public hospitals, universities and scientific associations. At the same time, listening to the needs of vulnerable social groups, Novartis Hellas contributed to the charity work of NGOs and structures, contributing also to the upgrading of educational process in border line schools, offering necessary technological equipment.

Susanne Kohout, President and Managing Director of Novartis Hellas, mentioned: "Despite challenges, we have managed to remain focused on our mission, to help Greek patients live longer and better lives in a way that is sustainable for Greek society and our company. We are proud of our footprint and based on innovation, we are committed to continue our work. "

"For Novartis, Corporate Responsibility is primarily connected to meeting and managing the needs and expectations of patients, caregivers, patient associations, health professionals, academic and scientific community, employees, partners, suppliers and other stakeholders, in the context of sustainability. Combining scientific developments and responsible attitude helps building relationships of trust with stakeholders while creating value for the company, patients and society. These relationships are the highest priority for us." said Foteini Bampanara, Head of Communications at Novartis.